Lehdistötiedote

Invitation to Saniona Q3 investor call on 27 November 2025

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, will host a Q3 investor call on 27 November 2025, at 11.00 CET

At the call Management will be presenting results and a company update. At the end of the presentation there will be a Q&A session, where participants can ask online questions.

Access to the event can be obtained through the following link:

https://www.redeye.se/events/1129462/live-q-saniona-3

REPLAY access
Webcast replay will be available at www.saniona.com and at www.redeye.se

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company’s internal pipeline includes SAN2668 for paediatric epilepsy syndromes, SAN2219 for epilepsy, and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico and Argentina, where a market authorization application is currently under review. In addition, Saniona has two clinical-stage programs available for partnering: Tesomet™, ready to advance to Phase 2b trials in rare eating disorders, and SAN903, ready to enter Phase 1 trials in inflammatory bowel disease. Saniona’s ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.